The Asd+-DadB+ dual-plasmid system offers a novel means to deliver multiple protective antigens by a recombinant attenuated Salmonella vaccine

Wei Xin, Soo Young Wanda, Xiangmin Zhang, Javier Santander, Giorgio Scarpellini, Karen Ellis, Praveen Alamuri, Roy Curtiss

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

We developed means to deliver multiple heterologous antigens on dual plasmids with non-antibiotic-resistance markers in a single recombinant attenuated vaccine strain of Salmonella enterica serotype Typhimurium. The first component of this delivery system is a strain of S. Typhimurium carrying genomic deletions in alr, dadB, and asd, resulting in obligate requirements for diaminopimelic acid (DAP) and D-alanine for growth. The second component is the Asd+-DadB+ plasmid pair carrying wildtype copies of asdA and dadB, respectively, to complement the mutations. To evaluate the protection efficacy of the dual-plasmid vaccine, S. Typhimurium strain Χ9760 (a strain with multiple attenuating mutations: Δasd Δalr ΔdadB ΔrecF) was transformed with Asd+ and DadB+ plasmids specifying pneumococcal antigens PspA and PspC, respectively. Both plasmids were stable in Χ9760 for 50 generations when grown in nonselective medium. This was significantly (P<0.05) greater than the stability seen in its recF+ counterpart Χ9590 and could be attributed to reduced interplasmid recombination in Χ9760. Oral immunization of BALB/c mice with 1 × 109 CFU of Χ9760 (carrying Asd+-PspA and DadB+-PspC plasmids) elicited a dominant Th1-type serum IgG response against both antigens and protected mice against intraperitoneal challenge with 200 50% lethal doses (LD50s) of virulent Streptococcus pneumoniae strain WU2 or intravenous challenge with 100 LD50s of virulent S. pneumoniae strain L81905 or intranasal challenge with a lethal dose of S. pneumoniae A66.1 in a pneumonia model. Protection offered by Χ9760 was superior to that offered by the mixture of two strains, Χ9828 (Asd+-PspA) and Χ11026 (DadB+-PspC). This novel dual-plasmid system marks a remarkable improvement in the development of live bacterial vaccines.

Original languageEnglish (US)
Pages (from-to)3621-3633
Number of pages13
JournalInfection and Immunity
Volume80
Issue number10
DOIs
StatePublished - Oct 2012

Fingerprint

Salmonella Vaccines
Attenuated Vaccines
Synthetic Vaccines
Plasmids
Antigens
Streptococcus pneumoniae
Diaminopimelic Acid
Bacterial Vaccines
Heterophile Antigens
Mutation
Salmonella enterica
Lethal Dose 50
Alanine
Genetic Recombination
Immunization
Pneumonia
Vaccines
Immunoglobulin G

ASJC Scopus subject areas

  • Immunology
  • Microbiology
  • Parasitology
  • Infectious Diseases

Cite this

The Asd+-DadB+ dual-plasmid system offers a novel means to deliver multiple protective antigens by a recombinant attenuated Salmonella vaccine. / Xin, Wei; Wanda, Soo Young; Zhang, Xiangmin; Santander, Javier; Scarpellini, Giorgio; Ellis, Karen; Alamuri, Praveen; Curtiss, Roy.

In: Infection and Immunity, Vol. 80, No. 10, 10.2012, p. 3621-3633.

Research output: Contribution to journalArticle

Xin, W, Wanda, SY, Zhang, X, Santander, J, Scarpellini, G, Ellis, K, Alamuri, P & Curtiss, R 2012, 'The Asd+-DadB+ dual-plasmid system offers a novel means to deliver multiple protective antigens by a recombinant attenuated Salmonella vaccine', Infection and Immunity, vol. 80, no. 10, pp. 3621-3633. https://doi.org/10.1128/IAI.00620-12
Xin, Wei ; Wanda, Soo Young ; Zhang, Xiangmin ; Santander, Javier ; Scarpellini, Giorgio ; Ellis, Karen ; Alamuri, Praveen ; Curtiss, Roy. / The Asd+-DadB+ dual-plasmid system offers a novel means to deliver multiple protective antigens by a recombinant attenuated Salmonella vaccine. In: Infection and Immunity. 2012 ; Vol. 80, No. 10. pp. 3621-3633.
@article{056fc61a022340c49c51bb9d1a7254e4,
title = "The Asd+-DadB+ dual-plasmid system offers a novel means to deliver multiple protective antigens by a recombinant attenuated Salmonella vaccine",
abstract = "We developed means to deliver multiple heterologous antigens on dual plasmids with non-antibiotic-resistance markers in a single recombinant attenuated vaccine strain of Salmonella enterica serotype Typhimurium. The first component of this delivery system is a strain of S. Typhimurium carrying genomic deletions in alr, dadB, and asd, resulting in obligate requirements for diaminopimelic acid (DAP) and D-alanine for growth. The second component is the Asd+-DadB+ plasmid pair carrying wildtype copies of asdA and dadB, respectively, to complement the mutations. To evaluate the protection efficacy of the dual-plasmid vaccine, S. Typhimurium strain Χ9760 (a strain with multiple attenuating mutations: Δasd Δalr ΔdadB ΔrecF) was transformed with Asd+ and DadB+ plasmids specifying pneumococcal antigens PspA and PspC, respectively. Both plasmids were stable in Χ9760 for 50 generations when grown in nonselective medium. This was significantly (P<0.05) greater than the stability seen in its recF+ counterpart Χ9590 and could be attributed to reduced interplasmid recombination in Χ9760. Oral immunization of BALB/c mice with 1 × 109 CFU of Χ9760 (carrying Asd+-PspA and DadB+-PspC plasmids) elicited a dominant Th1-type serum IgG response against both antigens and protected mice against intraperitoneal challenge with 200 50{\%} lethal doses (LD50s) of virulent Streptococcus pneumoniae strain WU2 or intravenous challenge with 100 LD50s of virulent S. pneumoniae strain L81905 or intranasal challenge with a lethal dose of S. pneumoniae A66.1 in a pneumonia model. Protection offered by Χ9760 was superior to that offered by the mixture of two strains, Χ9828 (Asd+-PspA) and Χ11026 (DadB+-PspC). This novel dual-plasmid system marks a remarkable improvement in the development of live bacterial vaccines.",
author = "Wei Xin and Wanda, {Soo Young} and Xiangmin Zhang and Javier Santander and Giorgio Scarpellini and Karen Ellis and Praveen Alamuri and Roy Curtiss",
year = "2012",
month = "10",
doi = "10.1128/IAI.00620-12",
language = "English (US)",
volume = "80",
pages = "3621--3633",
journal = "Infection and Immunity",
issn = "0019-9567",
publisher = "American Society for Microbiology",
number = "10",

}

TY - JOUR

T1 - The Asd+-DadB+ dual-plasmid system offers a novel means to deliver multiple protective antigens by a recombinant attenuated Salmonella vaccine

AU - Xin, Wei

AU - Wanda, Soo Young

AU - Zhang, Xiangmin

AU - Santander, Javier

AU - Scarpellini, Giorgio

AU - Ellis, Karen

AU - Alamuri, Praveen

AU - Curtiss, Roy

PY - 2012/10

Y1 - 2012/10

N2 - We developed means to deliver multiple heterologous antigens on dual plasmids with non-antibiotic-resistance markers in a single recombinant attenuated vaccine strain of Salmonella enterica serotype Typhimurium. The first component of this delivery system is a strain of S. Typhimurium carrying genomic deletions in alr, dadB, and asd, resulting in obligate requirements for diaminopimelic acid (DAP) and D-alanine for growth. The second component is the Asd+-DadB+ plasmid pair carrying wildtype copies of asdA and dadB, respectively, to complement the mutations. To evaluate the protection efficacy of the dual-plasmid vaccine, S. Typhimurium strain Χ9760 (a strain with multiple attenuating mutations: Δasd Δalr ΔdadB ΔrecF) was transformed with Asd+ and DadB+ plasmids specifying pneumococcal antigens PspA and PspC, respectively. Both plasmids were stable in Χ9760 for 50 generations when grown in nonselective medium. This was significantly (P<0.05) greater than the stability seen in its recF+ counterpart Χ9590 and could be attributed to reduced interplasmid recombination in Χ9760. Oral immunization of BALB/c mice with 1 × 109 CFU of Χ9760 (carrying Asd+-PspA and DadB+-PspC plasmids) elicited a dominant Th1-type serum IgG response against both antigens and protected mice against intraperitoneal challenge with 200 50% lethal doses (LD50s) of virulent Streptococcus pneumoniae strain WU2 or intravenous challenge with 100 LD50s of virulent S. pneumoniae strain L81905 or intranasal challenge with a lethal dose of S. pneumoniae A66.1 in a pneumonia model. Protection offered by Χ9760 was superior to that offered by the mixture of two strains, Χ9828 (Asd+-PspA) and Χ11026 (DadB+-PspC). This novel dual-plasmid system marks a remarkable improvement in the development of live bacterial vaccines.

AB - We developed means to deliver multiple heterologous antigens on dual plasmids with non-antibiotic-resistance markers in a single recombinant attenuated vaccine strain of Salmonella enterica serotype Typhimurium. The first component of this delivery system is a strain of S. Typhimurium carrying genomic deletions in alr, dadB, and asd, resulting in obligate requirements for diaminopimelic acid (DAP) and D-alanine for growth. The second component is the Asd+-DadB+ plasmid pair carrying wildtype copies of asdA and dadB, respectively, to complement the mutations. To evaluate the protection efficacy of the dual-plasmid vaccine, S. Typhimurium strain Χ9760 (a strain with multiple attenuating mutations: Δasd Δalr ΔdadB ΔrecF) was transformed with Asd+ and DadB+ plasmids specifying pneumococcal antigens PspA and PspC, respectively. Both plasmids were stable in Χ9760 for 50 generations when grown in nonselective medium. This was significantly (P<0.05) greater than the stability seen in its recF+ counterpart Χ9590 and could be attributed to reduced interplasmid recombination in Χ9760. Oral immunization of BALB/c mice with 1 × 109 CFU of Χ9760 (carrying Asd+-PspA and DadB+-PspC plasmids) elicited a dominant Th1-type serum IgG response against both antigens and protected mice against intraperitoneal challenge with 200 50% lethal doses (LD50s) of virulent Streptococcus pneumoniae strain WU2 or intravenous challenge with 100 LD50s of virulent S. pneumoniae strain L81905 or intranasal challenge with a lethal dose of S. pneumoniae A66.1 in a pneumonia model. Protection offered by Χ9760 was superior to that offered by the mixture of two strains, Χ9828 (Asd+-PspA) and Χ11026 (DadB+-PspC). This novel dual-plasmid system marks a remarkable improvement in the development of live bacterial vaccines.

UR - http://www.scopus.com/inward/record.url?scp=84867610365&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867610365&partnerID=8YFLogxK

U2 - 10.1128/IAI.00620-12

DO - 10.1128/IAI.00620-12

M3 - Article

VL - 80

SP - 3621

EP - 3633

JO - Infection and Immunity

JF - Infection and Immunity

SN - 0019-9567

IS - 10

ER -